New multifunctional di- tert -butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action

Journal of Medicinal Chemistry

Volumn 56, Issue 8, 2013, Pages 3330-3338

  Ladopoulou, Eleni ^a   Matralis, Alexios N ^a   Kourounakis, Angeliki P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3',5' DI TERT BUTYL 4' HYDROXY 4 BIPHENYL) 4 METHYLOCTAHYDRO 1,4 BENZOXAZIN OL HYDROBROMIDE; 3 (3',5' DI TERT BUTYL 4' HYDROXY 4 BIPHENYL)OCTAHYDROPYRIDO[2,1 C][1,4]OXAZIN 3 OL HYDROBROMIDE; 3,4 METHYLENEDIOXYAMPHETAMINE; ANTIDIABETIC AGENT; CHOLESTEROL; SQUALENE SYNTHASE; SUCCINOBUCOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAW EDEMA; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MICE; OXIDATIVE STRESS; PROBUCOL; RATS;

EID: 84876832822     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400101e     Document Type: Article

References (42)

1. Calkin, A. C.; Allen, T. J. Diabetes mellitus-associated atherosclerosis Am. J. Cardiovasc. Drugs 2006, 6, 15-40
2. Odegaard, J. W.; Chawla, A. Mechanisms of macrophage activation in obesity-induced insulin resistance Nat. Clin. Pract. Endocrinol. Metab. 2008, 4, 619-626
3. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
4. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
5. Chrysselis, M. C.; Rekka, E. A.; Kourounakis, P. N. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity J. Med. Chem. 2000, 43, 609-612
6. Kourounakis, A. P.; Charitos, C.; Rekka, E. A.; Kourounakis, P. N. Lipid-lowering (hetero) aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity J. Med. Chem. 2008, 51, 5861-5865
7. Kourounakis, A. P.; Matralis, A. N.; Nikitakis, A. Design of more potent squalene synthase inhibitors with multiple activities Bioorg. Med. Chem. 2010, 18, 7402-7412
8. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A. P.; Rekka, E. A.; Kourounakis, P. N.; Charalambous, A.; Manolopoulos, V. ER2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit J. Pharmacol. Exp. Ther. 2007, 323, 794-804
9. Muldrew, K. M.; Franks, A. M. Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects Expert Opin. Invest. Drugs 2009, 18, 531-539
10. Esterbauer, H.; Gebicki, J.; Puhl, H.; Jurgens, G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL Free Radical Biol. Med. 1992, 13, 341-390
11. Kuroda, M. K.; Tanzawa, K.; Tsujita, Y.; Endo, A. Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in triton WR-1339-induced hyperlipidemia Biochim. Biophys. Acta 1977, 489, 119-125
12. Bjorkhem, I.; Henriksson-Freyschuss, A.; Breuer, O.; Diczfalusy, U.; Berglund, L.; Henriksson, P. The antioxidant butylated hydroxytoluene protects against atherosclerosis Arterioscler., Thromb., Vasc. Biol. 1991, 11, 15-22
13. Tsiakitzis, K. C.; Rekka, E. A.; Kourounakis, A. P.; Kourounakis, P. N. Novel compounds designed as antistress agents J. Med. Chem. 2009, 52, 7315-7318
14. Di Rosa, M. G. J.; Willoughby, D. A. Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine J. Pathol. 1971, 104, 15-29
15. Hadjipetrou-Kourounakis, L.; Rekka, E.; Kourounakis, A. Suppression of adjuvant induced disease (AID) by a novel analgesic-opioid agonist which also possesses antioxidant activity Ann. N.Y. Acad. Sci. 1992, 650, 19-24
16. Doulgkeris, C. M.; Galanakis, D.; Kourounakis, A. P.; Tsiakitzis, K. C.; Gavala, D.; Eleftheriou, P. T.; Victoratos, P.; Rekka, E. A.; Kourounakis, P. N. Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties Bioorg. Med. Chem. Lett. 2006, 16, 825-829
17. Srinivasan, K.; Viswanad, B.; Asrat, L.; Kaul, C. L.; Ramarao, K. P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening Pharmacol. Res. 2005, 52, 313-320
18. Arulmozhi, D. K.; Kurian, R.; Bodhankar, S. L.; Veeranjaneyulu, A. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozotocin (MLDS) mouse model of diabetes J. Pharm. Pharmacol. 2008, 60, 1167-1173
19. Steiner, G. Atherosclerosis in type 2 diabetes: a role for fibrate therapy? Diabetes Vasc. Dis. Res. 2007, 4, 368-374
20. Kornbrust, D. J.; MacDonald, J. S.; Peter, C. P. Toxicity of the HMG coenzyme A reductase inhibitor, lovastatin, to rabbits J. Pharmacol. Exp. Ther. 1989, 248, 498-505
21. Masters, B. A.; Palmoski, M. J.; Flint, O. P.; Gregg, R. E.; Wang-Iverson, D.; Durham, S. K. In vitro myotoxicity of the 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes Toxicol. Appl. Pharmacol. 1995, 131, 163-174
22. Charlton-Menys, V.; Durrington, P. N. Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential Drugs 2007, 67, 11-16
23. Preiss, D.; Kondapally, S. R.; Welsh, P.; Murphy, S. A.; Ho, J. E.; Waters, D. D.; DeMicco, D. A.; Barter, P.; Cannon, C. P.; Sabatine, M. S.; Braunwald, E.; Kastelein, J. J. P.; de Lemos, J. A.; Blazing, M. A.; Pedersen, T. R.; Tikkanen, M. J.; Sattar, N.; Ray, K. K. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy JAMA, J. Am. Med. Assoc. 2011, 305, 2556-2564
24. Sattar, N.; Preiss, D.; Murray, H. M.; Welsh, P.; Bucklay, B. M.; de Graen, A. J. M.; Rao, S.; Seshasai, K.; McMurray, J. J.; Freeman, D. J.; Jukema, J. W.; Macfarlane, R. W.; Packard, C. J.; Stott, D. J.; Westendoro, R. G.; Shepherd, J.; Davis, B. R.; Pressel, S. L.; Marchioli, R.; Marfisi, R. M.; Maggioni, A. P.; Tavazzi, L.; Tognori, G.; Kiekshus, J.; Pedersen, T. R.; Cook, T. J.; Gotto, A. M.; Clearfield, M. B.; Downs, J. R.; Nakamura, H.; Ohashi, Y.; Mizuno, K.; Ray, K. K.; Ford, I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials Lancet 2010, 375, 735-742
25. Mallinson, J. E.; Constantin-Teodosiu, D.; Sidaway, J.; Westwood, F. R.; Greenhalf, P. L. Blunted Akt/FOXO signaling and activation of genes controlling atrophy and fuel use in statin myopathy J. Physiol. 2009, 587, 219-230
26. Kourounakis, A. P.; Katselou, M. G.; Matralis, A. N.; Ladopoulou, E. M.; Bavavea, E. Squalene synthase inhibitors: an update on the search for new antihyperlipidemic and antiatherosclerotic agents Curr. Med. Chem. 2011, 18, 4418-4439
27. Baynes, J. W.; Thorpe, S. R. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm Diabetes 1999, 48, 1-9
28. Davi, G.; Falco, A.; Patrono, C. Lipid peroxidation in diabetes mellitus Antioxid. Redox Signaling 2005, 7, 256-268
29. Butler, A. E.; Janson, J.; Bonner-Weir, S. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 2003, 52, 102-110
30. Leloup, C.; Tourrel-Cuzin, C.; Magnan, C.; Karaca, M.; Castel, J.; Carneiro, L.; Colombani, A. L.; Ktorza, A.; Casteilla, L.; Penicaud, L. Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion Diabetes 2009, 58, 673-681
31. Lo, M. C.; Lansang, C. L. Recent and emerging therapeutic medications in type 2 diabetes mellitus: Incretin-based pramlintide, colesevelam, SGLT2 inhibitors, tagatose, succinobucol Am. J. Ther. 2010, 10.1097/MJT. 0b013e3181ec9eb2
32. Stocker, R. Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues Curr. Opin. Lipidol. 2009, 20, 227-235
33. Crim, W. S.; Wu, R.; Carter, J. D.; Cole, B. K.; Trace, A. P.; Mirmira, R. G.; Kunsch, C.; Nadler, J. L.; Nunemaker, C. S. AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets Mol. Cell. Endocrinol. 2010, 323, 246-255
34. Agouni, A.; Lagrue-Lak-Hal, A. H.; Mostefai, H. A.; Tesse, A.; Mulder, P.; Rouet, P.; Desmoulin, F.; Heymes, C.; Martinèz, M. C.; Andriantsitohaiana, R. Red wine polyphenols prevent metabolic and cardiovascular alterations associated with obesity in Zucker fatty rats (Fa/Fa) PLoS One 2009, 5, e5557
35. RN1-type reaction J. Org. Chem. 1994, 59, 4482-4489
36. De Lassauniere, C. P. E.; Harnett, J.; Bigg, D.; Liberatore, A. M.; Pommier, J.; Lannoy, J.; Thurieau, C.; Dong, Z. X. Five-Membered Heterocycle Derivatives Useful as Monoamine Oxidase Inhibitors, Lipid Peroxidation Inhibitors, and Sodium Channel Modulators, and the Production and Use Thereof as Medicaments. U.S. Pat. Appl. Publ. US 2005038087 A1, 2005; 154 pp (Cont.-in-part of U.S. Ser. 681,002).
37. Havel, R. J.; Eder, H. A.; Bragdom, J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J. Clin. Invest. 1955, 34, 1345-1353
38. Jeong, T. S.; Kim, K. S.; Kim, J. R.; Cho, K. H.; Lee, W. S. Novel 3,5-diaryl pyrazolines and pyrazole as low-density lipoprotein (LDL) oxidation inhibitor Bioorg. Med. Chem. Lett. 2004, 14, 2719-2723
39. Amin, D.; Cornell, S. A.; Gustafson, S. K.; Needle, S. J.; Ullrich, J. W.; Bilder, G. E.; Perrone, M. H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis J. Lipid Res. 1992, 33, 1657-1663
40. Esterbauer, H.; Cheesemon, K. H. Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxynonenal Methods Enzymol. 1990, 186, 407-421
41. Xie, W.; Nie, Y.; Du, L.; Zhang, Y.; Cai, G. Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard Pharmacol. Res. 2007, 55, 392-399
42. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folin phenol reagent J. Biol. Chem. 1951, 193, 265-275